ArticlePloS one2026
Inhibition of neutrophil infiltration and NETs formation ameliorates neuropsychiatric and renal dysfunction in MRL/lpr mice with lupus.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcriptomic Challenges We Faced with Animal Models for Neurological Disorders.Current issues in molecular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with systemic lupus erythematosus often experience kidney and nervous system damage. It has been discovered that neutrophils and NETs play a significant role in lupus-related damage. However, whether inhibiting the infiltration of neutrophils into tissues can alleviate lupus-related brain and kidney damage remains unclear.
methodsLupus-prone MRL/lpr mice were assigned to four groups: MRL/MpJ control, MRL/lpr model, MRL/lpr + Avacopan, and MRL/lpr + Naringenin. Cognitive functions such as memory, emotion, and learning in the mice were assessed through open field tests, Y-maze tests, and water maze tests. Changes in kidney function were also evaluated in each group. Pathological changes in the brain and kidneys of the mice, as well as the infiltration of neutrophils and the expression of NETs-related markers NE and MPO, were observed using histopathological staining, immunohistochemistry, silver staining, and multiplex immunofluorescence staining. Additionally, changes in the expression of key inflammatory factors in the brain and kidneys were examined.
resultsAvacopan can improve cognitive function impairment and the progression of kidney damage in lupus-prone mice. Additionally, Avacopan has been found to reduce the infiltration of CD11b-positive and CD11b/CD16 double-positive cells into the brain and kidneys, as well as to decrease the expression of NETs-related markers NE and MPO. Notably, we observed that the main NETs marker in the kidneys of lupus mice is NE. Key inflammatory factors associated with lupus, such as IL-6, IL-17, and TNF-α, are found to be elevated in both the brain and kidney tissues of lupus mice, and Avacopan can reduce the expression of these inflammatory factors.
conclusionNeutrophils play a significant role in systemic lupus erythematosus-related brain and kidney damage. Inhibiting the infiltration of neutrophils can mitigate the inflammatory damage and NETs-related damage caused by their infiltration. However, the detailed mechanisms by which neutrophils cause tissue damage still need further clarification. For example, it remains to be explained why there is such substantial infiltration of neutrophils into tissues, what the cell signaling mechanisms involved in damage after neutrophil infiltration are, and whether there is any impact on the regulation of other immune cells such as macrophages and T lymphocytes. Further research is needed on these aspects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.